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METHODS: Patients were randomly assigned to intravenous reslizumab 3.0 mg/kg or placebo
once every 4 weeks for 16 weeks. The primary end point was the change in FEV1 from
baseline to week 16. Secondary measures included Asthma Control Questionnaire-7 (ACQ-7)
scores, use of short-acting b-agonists (SABAs), and FVC.
RESULTS: Four hundred ninety-two patients received $ 1 dose of placebo (n ¼ 97) or
reslizumab (n ¼ 395). In the overall population, mean FEV1 change from baseline to week 16
was not signiﬁcantly different between reslizumab and placebo, and no signiﬁcant
relationship was detected between treatment, baseline blood eosinophils and change in FEV1.
In the subgroup of patients with baseline eosinophils < 400 cells/mL, patients treated with
reslizumab showed no signiﬁcant improvement in FEV1 compared with those receiving
placebo. In the subgroup with eosinophils $ 400 cells/mL, however, treatment with
reslizumab was associated with much larger improvements in FEV1, ACQ-7, rescue SABA
use, and FVC compared with the placebo group. Reslizumab was well tolerated, with fewer
overall adverse events compared with placebo (55% vs 73%).
CONCLUSIONS: Reslizumab was well tolerated in patients with inadequately controlled
asthma. Clinically meaningful effects on lung function and symptom control were not seen in
patients unselected for baseline eosinophils.
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Asthma is a heterogeneous disease with multiple
phenotypes reﬂecting varying molecular, pathologic,
and physiologic processes.1,2 Several asthma
phenotypes are characterized by elevated eosinophil
levels in the lung, blood, and sputum.2,3 Eosinophils
play an important role in promoting and sustaining
airway inﬂammation, airway wall thickening, ﬁbrosis,
and angiogenesis.4 Increased blood and sputum
eosinophil counts have been correlated with increased
asthma severity and are independent risk factors for
asthma exacerbations.5,6
IL-5 is a key cytokine involved in the maturation,
recruitment, and activation of eosinophils.7 Speciﬁc
effects of IL-5 on eosinophils include inducing terminal
maturation, prolonging cell survival by delaying
apoptosis, increasing endothelial adhesion, and800 Original Researchenhancing effector function.4,7 Thus, abrogation of IL-5
activity represents a potentially important strategy for
reducing eosinophil-mediated inﬂammation in asthma.8
Reslizumab is a humanized anti-IL-5 monoclonal
(IgG4/k) antibody that binds circulating IL-5 with high
afﬁnity and prevents binding of IL-5 to its receptor.9
Reslizumab has been shown to reduce blood and sputum
eosinophils, improve pulmonary function, and reduce
asthma exacerbations in patients with elevated
sputum eosinophils or blood eosinophil counts $ 400
cells/mL.10-13 The current study was conducted in a
population with asthma unselected for baseline blood
eosinophil counts to determine the impact of baseline
eosinophil level on efﬁcacy and to help identify the
patient population most likely to beneﬁt clinically from
reslizumab.Methods
Study Design and Patients
This was a randomized, double-blind, placebo-controlled, phase 3 trial
conducted at 66 study locations across the United States
(NCT01508936). Eligible patients were 18 to 65 years with asthma
(Asthma Control Questionnaire [ACQ]-7 score $ 1.5) inadequately
controlled by at least a medium-dose inhaled corticosteroid (ICS) at
screening (ﬂuticasone propionate $ 440 mg/day, or equivalent).
Other permitted baseline medications included long-acting
b-agonists (LABAs), leukotriene-receptor antagonists, 5-lipoxengase
inhibitors, or cromolyn, provided the regimen was stable for 30 days
before screening and not expected to change throughout the study;
maintenance oral corticosteroids were not allowed. Patients were
required to demonstrate airway reversibility ($ 12% to short-acting
b-agonist [SABA]) at screening. The population did not select for
patients based on blood eosinophil counts, and there was no limit on
FEV1 for entry. Exclusion criteria are outlined in e-Appendix 1. The
study was conducted in accordance with the International
Conference on Harmonization Good Clinical Practice Guidelines and
was approved by local ethics review committees (e-Table 1). All
patients provided written informed consent.
Study Procedures and Assessments
The study consisted of a 3-week screening period, a 16-week double-
blind treatment period, and a 12-week follow-up period. Patients
were randomly assigned (4:1) to reslizumab 3.0 mg/kg or placebo
given intravenously once every 4 weeks during the treatment period
(total of 4 doses), stratiﬁed by the occurrence of exacerbations in the
12 months before screening (yes/no). Patients were to refrain from
using SABAs for 6 h and LABAs for 12 h before study visits. The
ﬁrst visit during the treatment period (week 0) was the baseline visit,
followed by visits at weeks 4, 8, 12, and 16. During visits, treatment
efﬁcacy was assessed by spirometric measures of pulmonary
function; safety was evaluated at speciﬁed time points throughout
the study. Patients were discontinued from treatment for asthma
exacerbations requiring systemic corticosteroids.
End Points and Outcome Measures
The primary end point was the change in FEV1 from baseline to week
16. Secondary end points included ACQ-7 score14; rescue (SABA) usewithin the previous 3 days (assessed using 3-day recall at scheduled
visits); FVC; and blood eosinophils (standard complete blood count).
ACQ-6 (excludes lung function domain) was analyzed post hoc.
Safety was evaluated by adverse events (AEs), coded using the
Medical Dictionary for Regulatory Activities v15.0. Blood samples
were collected for antidrug antibodies (ADAs) determination at
baseline, weeks 8 and 16 (end of therapy or at early withdrawal),
and at follow-up, and analyzed by Teva Biopharmaceuticals
(Rockville, MD) using a validated homogeneous solution-based
bridging enzyme-linked immunosorbent assay.15,16 All cut-point
calculations were performed according to recommended statistical
methods.17,18
Statistical Analysis
Unless otherwise stated, efﬁcacy analyses were based on the full
analysis set (FAS), including all patients treated with $ 1 dose of
study drug. Results from patients using concomitant medication
(including oral or systemic corticosteroids or addition of an LABA
or a long-acting antimuscarinic agent if not taken at baseline) within
7 days preceding a scheduled visit that could signiﬁcantly confound
interpretation of the efﬁcacy parameters were excluded from the
FAS. A blind data review meeting was conducted before the database
lock to determine the exclusion of affected, individual pulmonary
function tests, ACQ, and SABA assessments. Sensitivity analyses
without data exclusion are presented in e-Appendix 2.
The primary efﬁcacy variable was FEV1 at week 16. The primary end
point was analyzed using a linear regression model with model
effects including treatment (reslizumab or placebo), blood
eosinophils at baseline, and the interaction of treatment and
eosinophils. The interaction was tested at the signiﬁcance level 0.10
using the FAS. A secondary analysis was performed for the primary
variable for patients included in the FEV1 subpopulation (all patients
in the FAS with % predicted FEV1 < 85% at baseline) using the
same linear regression analysis described above. Change in FEV1 by
discrete blood eosinophil thresholds was prespeciﬁed; a post hoc
analysis of FEV1, FVC, and ACQ-7 stratiﬁed by eosinophil quartile
categories was also performed. Secondary variables, including change
in FEV1 from baseline to planned time points, were analyzed using a
mixed effects model for repeated measures. Analyses of secondary
variables are further described in e-Appendix 3.[ 1 5 0 # 4 CHES T OC TO B E R 2 0 1 6 ]
Results
Patients
A total of 869 patients were screened; 98 were randomly
assigned to placebo and 398 to reslizumab (Fig 1);
492 (> 99%) received $ 1 dose of study drug and were
included in the FAS (4 patients withdrew before taking
any study drug). A total of 82 patients (84%) treated
with placebo and 340 patients (85%) treated with
reslizumab completed treatment. The most common
reason for withdrawal or study discontinuation was an
AE (12% placebo, 8% reslizumab).
At baseline, the treatment groups were comparable
with respect to demographic and asthma characteristics
(Table 1). Similar proportions in each group reported
experiencing an asthma exacerbation during the
12 months before study entry (Table 1). Eosinophils
$ 400 cells/mL were observed in 20% of patients atPatients sc
(N = 86
Patients rand
(n = 49
Patients
withdrawn
(n = 16 [16%])
Patients
completed
(n = 82 [84%])
Reason for withdrawal
Adverse event (n = 12 [12%])
Protocol violation (n = 2 [2%])
Consent withdrawn (n = 1 [1%])
Lost to follow-up (n = 1 [1%])
Screened but not randomized
(n = 358)
Inclusion criteria not met (n = 267)
Exclusion criteria met (n = 42)
Consent withdrawn (n = 20)
Other (n = 16)
Lost to follow-up (n = 7)
Adverse event (n = 6)
Placebo
(n = 98)
Stratified by asthma exacerbation in last 12 mo
   • Yes: n = 40 (41%)
   • No: n = 58 (59%)
Evaluable for safety (n = 97 [99%])
Evaluable for efficacy (n = 97 [99%])
FEV1 subpopulation (n = 91 [93%])
Figure 1 – Patient disposition (all patients).
journal.publications.chestnet.orgbaseline, and were distributed similarly between
treatment groups.
Efﬁcacy Outcomes
Mean change in FEV1 from baseline to week 16 was
255 mL (reslizumab group) and 187 mL (placebo
group), with a between-group difference of 68 mL
(SE,  49.5; P ¼ .17) (Fig 2, Table 2). A positive
relationship was observed between baseline blood
eosinophils and change from baseline in FEV1 for
reslizumab (slope, 0.0229) with a negative relationship
observed for placebo (slope, –0.2778) based on linear
regression; however, the interaction between treatment
and the relationship between baseline eosinophils and
FEV1 did not achieve statistical signiﬁcance (slope
difference, 0.3; SE,  0.26; P ¼ .24) (Fig 3). A sensitivity
analysis using all FEV1 measurements without data
exclusions for concomitant medication violations wasreened
9)
omized
6)
Patients
withdrawn
(n = 58 [15%])
Patients
completed
(n = 340 [85%])
Reason for withdrawal
Adverse event (n = 32 [8%])
Consent withdrawn (n = 9 [2%])
Lost to follow-up (n = 5 [1%])
Lack of efficacy (n = 1 [< 1%])
Protocol violation (n = 3 [< 1%])
Other (n = 8 [2%])
Reslizumab 3.0 mg/kg
(n = 398)
Stratified by asthma exacerbation in last 12 mo
   • Yes: n = 160 (40%)
   • No: n = 238 (60%)
Evaluable for safety (n = 395 [> 99%])
Evaluable for efficacy (n = 395 [> 99%])
FEV1 subpopulation (n = 346 [87%])
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TABLE 1 ] Baseline Patient and Disease Characteristics
Characteristic Placebo (n ¼ 98) Reslizumab 3.0 mg/kg (n ¼ 398)
Mean age, y 45.1 44.9
Sex, No. (%)
Female 54 (55) 261 (66)
Male 44 (45) 137 (34)
Race, No. (%)
White 73 (74) 260 (65)
Black 21 (21) 113 (28)
Asian 2 (2) 10 (3)
BMI, mean, kg/m2 31.6 32.3
Years since diagnosis, mean 25.8 26.2
ICS use at enrollment, mean, mg/d 627.8 615.7
Exacerbation within previous 12 mo, No. (%) 37 (38) 166 (42)
ACQ score, mean 2.564 2.558
Airway reversibility, % 24.2 26.0
FEV1, mean, L 2.180 2.101
FEV1, % predicted 66.5 66.8
Rescue medication use, mean inhalations/previous 3 d 2.0 1.9
Blood eosinophils, mean (range), cells/mL 277 (0-1,288) 281 (0-1,584)
Treated with LABA, % 80 (82) 307 (77)
ACQ ¼ Asthma Control Questionnaire; ICS ¼ inhaled corticosteroid; LABA ¼ long-acting b-agonist.
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Figure 2 – LS mean ( SE) change from baseline to each visit in FEV1 by
treatment group (full analysis set). LS ¼ least squares.consistent with the primary analysis using the FAS
(slope difference, 0.31; SE,  0.26; P ¼ .23). A sensitivity
analysis based on an ostensibly less well-controlled
subpopulation based on lower baseline lung function
(% predicted FEV1 # 85% at baseline) did not alter this
relationship signiﬁcantly (slope difference, 0.3215; SE,
 0.2643; P ¼ .22).
This study was not adequately powered to test the
efﬁcacy of reslizumab across multiple eosinophil
subgroups. Keeping this design limitation in mind,
we determined that 80% of the study population had
a blood eosinophil count of < 400 cells/mL at
randomization. The difference in change in FEV1 from
baseline to week 16 between the reslizumab (n ¼ 275)
and placebo treatment (n ¼ 68) groups in the subgroup
with eosinophils < 400 cells/mL was 33 mL (P ¼ .54).
The difference in change in FEV1 in patients with
eosinophils $ 400/mL between the reslizumab (n ¼ 69)
and placebo (n ¼ 13) groups was 270 mL (P ¼ .04)
(Figs 4A and 4B, Table 2). The magnitude of the
treatment difference in this subgroup appears to have
been primarily inﬂuenced by a near complete lack of
response in the small number of patients treated with
placebo. Analysis of the FEV1 treatment effect in
patients with < 400 cells/mL across a range of cutoffs
did not show a meaningful trend (Fig 4B). A sensitivity802 Original Researchanalysis without data exclusion for concomitant
medication violations was consistent with the primary
analysis (e-Table 2). A post hoc analysis of FEV1 by
baseline eosinophil quartiles (Fig 4C) was performed; no
effect was observed at very low eosinophil counts, with
positive changes in FEV1 observed only for the upper
quartiles.
The pattern of improvements in other efﬁcacy
parameters (ACQ-7, ACQ-6, FVC, and SABA use) at
16 weeks was consistent with that observed for FEV1.
Speciﬁcally, improvements relative to placebo in the
overall population were modest (Table 2), although a[ 1 5 0 # 4 CHES T OC TO B E R 2 0 1 6 ]
TABLE 2 ] Change From Baseline to Week 16 for Efﬁcacy Variables by Baseline Eosinophil Count
Efﬁcacy Variable
Overall Population Baseline Eosinophils < 400 cells/mL Baseline Eosinophils $ 400 cells/mL
Placebo Reslizumab, 3.0 mg/kg Placebo Reslizumab, 3.0 mg/kg Placebo Reslizumab, 3.0 mg/kg
FEV1, L
No. 97 394 76 316 19 77
Baseline mean  SE 2.172  0.0643 2.098  0.0350 2.182  0.0746 2.068  0.0372 2.153  0.1392 2.224  0.0928
Mean change from baseline  SE 0.187  0.0446 0.255  0.0232 0.215  0.0484 0.247  0.0255 0.002  0.1216 0.272  0.0557
Treatment effect change  SE 0.068  0.0495 0.033  0.0539 0.270  0.1320
95% CI –0.030 to 0.165 –0.073 to 0.139 0.008 to 0.532
P value .1719 .5422 .0436
FVC, L
No. 97 394 76 316 19 77
Baseline mean  SE 3.209  0.0924 3.041  0.0481 3.217  0.1095 2.973  0.0513 3.206  0.1757 3.321  0.1234
Mean change from baseline  SE 0.236  0.0506 0.247  0.0263 0.256  0.0537 0.248  0.0283 0.055  0.1449 0.230  0.0681
Treatment effect change  SE 0.012  0.0560 –0.009  0.0598 0.175  0.1571
95% CI –0.098 to 0.122 –0.126 to 0.109 –0.137 to 0.487
P value .8361 .8853 .2675
ACQ–7a
No. 97 394 76 316 19 77
Baseline mean  SE 2.574  0.0698 2.559  0.0353 2.564  0.0778 2.574  0.0390 2.677  0.1692 2.501  0.0839
Mean change from baseline  SE –0.648  0.0878 –0.844  0.0453 –0.714  0.0954 –0.836  0.0499 –0.368  0.2407 –0.858  0.1105
Treatment effect change  SE –0.195  0.0974 –0.122  0.1065 –0.490  0.2616
95% CI –0.387 to –0.004 –0.332 to 0.087 –1.010 to 0.030
P value .0457 .2511 .0643
SABA use, puffs/day
No. 96 392 76 315 18 76
Baseline mean  SE 2.0  0.19 1.9  0.09 2.0  0.21 1.9  0.10 2.2  0.44 1.9  0.21
Mean change from baseline  SE –0.4  0.19 –0.3  0.10 –0.4  0.21 –0.2  0.11 –0.1  0.43 –0.8  0.19
Treatment effect change  SE 0.063  0.2050 0.216  0.2300 –0.708  0.4587
95% CI –0.340 to 0.466 –0.236 to 0.668 –1.619 to 0.204
P value .7589 .3484 .1264
Mean change from baseline expressed as least squares mean with associated SE. SABA ¼ short-acting b-agonist. See Table 1 legend for expansion of other abbreviation.
aNegative changes in ACQ indicate improved asthma control. The minimal clinically important difference for ACQ is 0.5 units.
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Figure 3 – Change in FEV1 (wk 16) vs baseline eosinophils: linear regression model (full analysis set).greater proportion of patients achieved a clinically
meaningful decrease in ACQ-7 score of$ 0.5 at week 16
with reslizumab (71%) vs placebo (57%; P ¼ .01). The
treatment effect in the subgroup of patients with blood
eosinophils < 400 cells/mL was small. In patients with
baseline blood eosinophils $ 400 cells/mL, increases in
these measures were more substantial, although not
signiﬁcant (Figs 5 and 6, Table 2, e-Fig 1, e-Table 3);
treatment effects for ACQ-7, FVC, and SABA use were
–0.49 units, 175 mL, and –0.71 inhalations, respectively.
Similar to FEV1, treatment effects in the $ 400 cells/mL
subgroup were at least in part accounted for by a low
placebo response.
A marked decrease in blood eosinophils was observed
after the ﬁrst dose of reslizumab compared with placebo
and was maintained during the 16 weeks, consistent
with the known mechanism of action of reslizumab
(overall treatment difference, –260 cells/mL; P < .0001)
(Fig 7). Mean blood eosinophil count began to return
toward baseline by the follow-up visit (3 months after
the end-of-treatment visit and approximately 4 months
after last the reslizumab dose).Safety and Tolerability
Reslizumab was generally well tolerated. A smaller
proportion of patients treated with reslizumab (55%)804 Original Researchexperienced $ 1 AE compared with those treated with
placebo (74%). Similarly, there were fewer AEs
considered by the investigator to be treatment-related
(7% vs 16%) and fewer discontinuations due to AEs
(8% vs 12%) with reslizumab than placebo. The
most common discontinuation AE in either group was
asthma (reslizumab 5%, placebo 8%); discontinuations
were otherwise single-patient events not predominated
by any particular system organ class. Equal proportions
(16 patients [4%] in the reslizumab group and 4 [4%]
in the placebo group) had serious AEs. The most frequent
($ 3%) AEs in the reslizumab group were asthma, upper
respiratory tract infection, and sinusitis (Table 3). A
greater percentage of infections were reported in the
placebo group (47%) than in the reslizumab group
(31%). Two patients in the reslizumab group had
anaphylaxis (one event was related to ongoing allergen
immunotherapy; one was associated with reslizumab).
For the reaction related to reslizumab, symptoms of
wheezing, shortness of breath, and ﬂushing occurred
shortly after infusion, without hemodynamic
compromise. The patient responded to epinephrine,
salbutamol, antihistamine, and prednisone at the study
site, and subsequently tested ADA-negative. One patient
in the reslizumab group had colon cancer (onset day 64),
which was not considered treatment-related. No deaths
occurred in either treatment group.[ 1 5 0 # 4 CHES T OC TO B E R 2 0 1 6 ]
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Figure 4 – A–C, Effect on FEV1 at wk 16 by change from baseline in patients with eosinophils $ 400 cells/mL and < 400 cells/mL (A), treatment
difference vs placebo by baseline eosinophil strata (full analysis set) (B), and treatment difference vs placebo by additional baseline eosinophil quartiles
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Figure 6 – A–C, Effect on ACQ-7 at wk 16 by change from baseline in patients with eosinophils $ 400 cells/mL and < 400 cells/mL (A), treatment
difference vs placebo by baseline eosinophil strata (full analysis set) (B), and treatment difference vs placebo by additional baseline eosinophil quartiles
(C). *P ¼ .0643 for reslizumab vs placebo. Error bars are SE of least squares mean (A), SE of the difference between reslizumab and placebo (B;
treatment difference and corresponding SE are from mixed model repeated measures), or SE of the difference between reslizumab and placebo (C).
ACQ-7 ¼ Asthma Control Questionnaire-7.
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Figure 7 – Blood eosinophils over time by treatment group (all ran-
domized patients). *The follow-up visit was conducted 12 wks  7 days
after the end of treatment at wk 16 or early withdrawal. See Figure 2
legend for expansion of abbreviation.Serum chemistry, hematology, urinalysis, physical
examination, vital signs, and electrocardiogram did not
reveal any clinically meaningful treatment effect with the
exception of the expected pharmacological effect ofTABLE 3 ] Adverse Events Occurring in $ 3% of
Patients in Either Group by Preferred
Term (Medical Dictionary for Regulatory
Activities 15.0)
AE
Placebo
(n ¼ 97)
Reslizumab
(n ¼ 395)
Asthma 19 (20) 50 (13)
Upper respiratory tract
infection
11 (11) 42 (11)
Sinusitis 7 (7) 22 (6)
Bronchitis 6 (6) 14 (4)
Nasopharyngitis 5 (5) 13 (3)
Headache 4 (4) 13 (3)
Urinary tract infection 0 10 (3)
Allergic rhinitis 3 (3) 9 (2)
Inﬂuenza 3 (3) 8 (2)
Acute sinusitis 3 (3) 6 (2)
Back pain 3 (3) 6 (2)
Diarrhea 3 (3) 4 (1)
Viral gastroenteritis 3 (3) 4 (1)
Oropharyngeal pain 3 (3) 4 (1)
Nausea 5 (5) 3 (< 1)
Arthralgia 4 (4) 3 (< 1)
Dizziness 3 (3) 3 (< 1)
Contusion 3 (3) 3 (< 1)
Dysgeusia 3 (3) 1 (< 1)
Gastroenteritis 3 (3) 0
Data are presented as No. (%). AE ¼ adverse event.
808 Original Researchreslizumab (eosinophil reduction with a slight,
proportionate impact on total white blood cell counts).
Three percent of patients treated with reslizumab tested
ADA-positive at screening before drug exposure, and
5% of patients treated with reslizumab were classiﬁed as
ADA-positive during treatment. Most ADA responses
were low titer and transient; only three patients (1%)
treated with reslizumab tested positive at $ 2
postbaseline assessments. There was no impact of
ADA-positive status on the AE proﬁle compared with
the overall population, or on eosinophil depletion by
reslizumab, consistent with a lack of neutralizing activity.
Discussion
Reslizumab has previously been demonstrated to
improve asthma control and pulmonary function in
asthma patients with blood eosinophils $ 400 cells/mL
who were uncontrolled with ICS and LABA treatment
in three large pivotal trials.12,13 The current study
was designed to explore the effect of reslizumab in
a population with asthma unselected for baseline
eosinophils. The results demonstrate that, in contrast
to the results of prior studies of patients with
elevated blood eosinophils, four once-monthly doses
of reslizumab 3.0 mg/kg given to patients with
inadequately controlled asthma unselected for
eosinophil count produced only modest effects on FEV1
compared with placebo (68 mL). The overall group
also had small improvements in FVC, ACQ, and
SABA use with reslizumab treatment. A positive
relationship between baseline eosinophil count and
FEV1 improvement was observed in the reslizumab
treatment group; however, the interaction between
this relationship and treatment was not signiﬁcant.
Secondary analyses showed small improvements in
efﬁcacy measures in the subgroup of patients with a
blood eosinophil count < 400 cells/mL. In contrast,
substantial improvements in FEV1, FVC, ACQ, and
SABA use were seen in the subgroup with $ 400
cells/mL at baseline.
Interpretation of the results in the $ 400 cells/mL
subgroup is limited as the study was not designed or
statistically powered to speciﬁcally test this group of
patients. Only 20% of the study population had a blood
eosinophil count of $ 400 cells/mL at randomization,
and only 13 patients treated with placebo met this
criterion. The ﬂat response of these 13 patients treated
with placebo contributed, in part, to the overall
treatment effect in this category. The small observed
placebo effect in the subgroup with blood eosinophils[ 1 5 0 # 4 CHES T OC TO B E R 2 0 1 6 ]
$ 400 cells/mL may have occurred by chance given the
very small sample size; there were no ostensible
differences in baseline control measures for patients
treated with placebo with blood eosinophils $ 400 cells/
mL vs patients treated with placebo with eosinophils
< 400 cells/mL (data not shown). Efﬁcacy analyses based
on eosinophil quartile results, which are more balanced,
support that an eosinophilic phenotype is essential to
reslizumab efﬁcacy as patients with very low eosinophil
counts had no meaningful response. This result is
consistent with observations that higher blood
eosinophil levels have been shown to be more speciﬁc
for airway eosinophilia,19,20 and are associated with
indicators of more severe disease, including low lung
function21-23 and greater asthma exacerbation risk.6
To date, clinical trials of other anti-IL-5 agents have
demonstrated improvements in FEV1 in some
studies24,25 but not in others.26,27 In a recent phase 2
benralizumab study that included patients with a broad
range of blood eosinophil counts, the threshold value
associated with meaningful lung function improvements
was$ 300 cells/mL.24 A subgroup analysis of data from a
phase 3 study of mepolizumab in refractory eosinophilic
asthma showed that the magnitude of improvement in
FEV1 with mepolizumab was larger in patients with
baseline blood eosinophils $ 500 cells/mL vs the overall
population (study inclusion $ 150 cells/mL at screening
or $ 300 cells/mL during the previous 12 months;
baseline geometric mean blood eosinophils, 280–320
cells/mL).25 The results from these studies suggest that
lung function response to an IL-5 inhibitor is inﬂuenced
by a patient’s baseline blood eosinophil level.
Due to the sample size and the short duration of the
current study, we were not able to perform a meaningful
assessment of the impact of blood eosinophil levels
on the reduction of asthma exacerbation events by
reslizumab (not formally assessed in this study).journal.publications.chestnet.orgA reduction in the annual rate of asthma exacerbations
by reslizumab 3.0 mg/kg has previously been
demonstrated in patients selected for elevated blood
eosinophils.12 Furthermore, meaningful reductions in
the annual rate of asthma exacerbations have been shown
for other anti-IL-5 and antieosinophil mechanisms of
action (ie, mepolizumab and benralizumab24,25) at
blood eosinophil cutoffs as low as $ 150 cells/mL.
Reslizumab treatment was well tolerated in this study,
with an AE proﬁle typical of patients with inadequately
controlled asthma. Overall, the incidence of AEs was less
frequent in the reslizumab group than the placebo
group, consistent with previous reslizumab studies.10-12
AEs resulting in withdrawal from the study were
uncommon, occurring with a frequency similar to
placebo with no predominant event pattern. There was a
single report of anaphylaxis during reslizumab infusion
that resolved with treatment at the study site. As the
ADA assessment was ultimately negative in this patient,
the event may be more consistent with an infusion
reaction than true drug hypersensitivity, although an
immune-mediated reaction cannot be completely
excluded by the negative ADA status. Since the reaction
occurred immediately after infusion and was easily
managed by the treating physician, the risks from these
types of reactions with a biologic can be mitigated when
administered by a health-care provider experienced in
the recognition and treatment of anaphylaxis.
In conclusion, reslizumab 3.0 mg/kg was well tolerated
in patients with asthma inadequately controlled on a
medium- to high-dose ICS-based regimen. Reslizumab
did not meaningfully improve asthma outcomes,
including both lung function and measures of symptom
control, in patients with blood eosinophil counts < 400
cells/mL. These ﬁndings support an acceptable beneﬁt-
risk proﬁle for reslizumab in patients with asthma who
have a blood eosinophil threshold of $ 400 cells/mL.809
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